Extracellular vesicles as natural nanosized delivery systems for small-molecule drugs and genetic material: Steps towards the future nanomedicines

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 18, Issue 3, 2015, Pages 396-413

  Kotmakçı, Mustafa ^a   Çetintaş, Vildan B ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CUCURBITACIN; CURCUMIN; DOXORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NANOPARTICLE; PACLITAXEL; SMALL MOLECULE TRANSPORT AGENT;

ARTICLE; BIOGENESIS; BLOOD BRAIN BARRIER; CELL MATURATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; EXOSOME; GENETIC TRANSFECTION; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MEMBRANE MICROPARTICLE; NANOMEDICINE; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; ANIMAL; CELL MEMBRANE; DRUG EFFECTS; GENE TRANSFER; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TRENDS;

ANIMALS; CELL MEMBRANE; CELL-DERIVED MICROPARTICLES; DRUG DELIVERY SYSTEMS; EXOSOMES; EXTRACELLULAR VESICLES; GENE TRANSFER TECHNIQUES; HUMANS; NANOMEDICINE; NANOPARTICLES; TISSUE DISTRIBUTION;

EID: 84941370080     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J36W3X     Document Type: Article

References (130)

1. Basavaraj S, Betageri G V. Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges. Acta Pharm Sin B. 2014;4(1):3–17.
2. Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release. 2008;132(3):153–63.
3. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020–37.
4. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36:43–8.
5. Nazar MF, Khan AM, Shah SS. Microemulsion system with improved loading of piroxicam: a study of microstructure. AAPS PharmSciTech. 2009;10(4):1286–94.
6. Wei T, Liu J, Ma H, Cheng Q, Huang Y, Zhao J, et al. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 2013;13(6):2528–34.
7. Dang Y-J, Zhu C-Y. Oral bioavailability of cantharidin-loaded solid lipid nanoparticles. Chin Med. 2013;8(1):1.
8. Abd-Allah FI, Dawaba HM, Ahmed AM. Development of a microemulsion-based formulation to improve the availability of poorly water-soluble drug. Drug Discov Ther. 2010;4(4):257–66.
9. Jesson G, Brisander M, Andersson P, Demirbüker M, Derand H, Lennernäs H, et al. Carbon dioxide-mediated generation of hybrid nanoparticles for improved bioavailability of protein kinase inhibitors. Pharm Res. 2014;31(3):694–705.
10. Dwivedi P, Khatik R, Khandelwal K, Taneja I, Raju KSR, Wahajuddin, et al. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm. 2014;466(1-2):321–7.
11. Singh G, Pai RS. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin Drug Deliv. 2014;11(5):647–59.
12. Joshi G, Kumar A, Sawant K. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci. 2014;60:80–9.
13. Gaur PK, Mishra S, Bajpai M, Mishra A. Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. Biomed Res Int. 2014;2014:363404.
14. Kotmakchiev M, Kantarcı G, Çetintas VB, Ertan G. Cytotoxicity of a Novel Oil / Water Microemulsion System Loaded with Mitomycin-C in In Vitro Lung Cancer Models. Drug Dev Res. 2012;195:185–95.
15. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, et al. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesionmediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012;2(4):e64.
16. Azzi J, Tang L, Moore R, Tong R, El Haddad N, Akiyoshi T, et al. Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J. 2010;24(10):3927–38.
17. Casa DM, Moraes Carraro TCM, De Camargo LEA, Dalmolin LF, Khalil NM, Mainardes RM. Poly(L-lactide) Nanoparticles Reduce Amphotericin B Cytotoxicity and Maintain Its In VitroAntifungal Activity. J Nanosci Nanotechnol. American Scientific Publishers; 2015;15(1):848–54.
18. Amaral AC, Bocca AL, Ribeiro AM, Nunes J, Peixoto DLG, Simioni AR, et al. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J Antimicrob Chemother 2009;63(3):526–33.
19. Chen JP, Yang PC, Ma YH, Tu SJ, Lu YJ. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. Int J Nanomedicine. 2012;7:5137–49.
20. Oh B, Han J, Choi E, Tan X, Lee M. Peptide Micelle-Mediated Delivery of Tissue-Specific Suicide Gene and Combined Therapy with Avastin in a Glioblastoma Model. J Pharm Sci. 2015;104(4):1461–9.
21. Leung AKK, Tam YYC, Cullis PR. Lipid nanoparticles for short interfering RNA delivery. Adv Genet. 2014;88:71–110.
22. Sun Z, Song X, Li X, Su T, Qi S, Qiao R, et al. In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. Nanoscale. 2014;6(23):14343–53.
23. Han J, Cai J, Borjihan W, Ganbold T, Rana TM, Baigude H. Preparation of novel curdlan nanoparticles for intracellular siRNA delivery. Carbohydr Polym. 2015;117:324–30.
24. Afonin KA, Viard M, Kagiampakis I, Case CL, Dobrovolskaia MA, Hofmann J, et al. Triggering of RNA Interference with RNARNA, RNA-DNA, and DNA-RNA Nanoparticles. ACS Nano. 2014;9(1):251–9.
25. Liu J, Zhang B, Luo Z, Ding X, Li J, Dai L, et al. Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale. 2015;7(8):3614–26.
26. Mansourpour M, Mahjub R, Amini M, Ostad SN, Shamsa ES, Rafiee-Tehrani M, et al. Development of Acid-Resistant Alginate/Trimethyl Chitosan Nanoparticles Containing Cationic β-Cyclodextrin Polymers for Insulin Oral Delivery. AAPS PharmSciTech. 2015;16(4):952-62.
27. Sivasubramanian M, Lee J-Y, Kim KJ, Saravanakumar G, Kang YM, Park JH. Cyclodextrin-based nanocomplexes for sustained delivery of human growth hormone. J Nanosci Nanotechnol. 2013;13(11):7306–11.
28. Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology. 2010;151(2):458–65.
29. Ray PC, Yu H, Fu PP. Toxicity and environmental risks of nanomaterials: challenges and future needs. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27(1):1–35.
30. Dhawan A, Sharma V, Parmar D. Nanomaterials: A challenge for toxicologists. Nanotoxicology. 2009;3(1):1–9.
31. Dhawan A, Sharma V. Toxicity assessment of nanomaterials: methods and challenges. Anal Bioanal Chem. 2010;398(2):589–605.
32. Shukla S, Jadaun A, Arora V, Sinha RK, Biyani N, Jain VK. In vitro toxicity assessment of chitosan oligosaccharide coated iron oxide nanoparticles. Toxicol Reports. 2015;2:27–39.
33. Chen WC, May JP, Li S-D. Immune responses of therapeutic lipid nanoparticles. Nanotechnol Rev. 2013;2(2):201–13.
34. Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, et al. Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol Ther Nucleic Acids. 2014;3:e210.
35. Chan VSW. Nanomedicine: An unresolved regulatory issue. Regul Toxicol Pharmacol. 2006;46:218–24.
36. Scott-Fordsmand JJ, Pozzi-Mucelli S, Tran L, Aschberger K, Sabella S, Vogel U, et al. A unified framework for nanosafety is needed. Nano Today. 2014;9(5):546–9.
37. El-Ansarya, Al-Daihan S. On the toxicity of therapeutically used nanoparticles: an overview. J Toxicol. 2009;2009:754810.
38. Mogharabi M, Abdollahi M, Faramarzi MA. Toxicity of nanomaterials; an undermined issue. DARU J Pharm Sci. 2014;22(1):59.
39. HALFORD B. NANOTOXICITY. In vivo study of fullerenes contradicts in vitro data. Chem Eng News. 2007;85(30):11a.
40. Hartung T. Look back in anger - what clinical studies tell us about preclinical work. ALTEX. 2013;30(3):275–91.
41. Xue HY, Liu S, Wong HL. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond). 2014;9(2):295–312.
42. Gangoda L, Boukouris S, Liem M, Kalra H, Mathivanan S. Extracellular vesicles including exosomes are mediators of signal transduction: Are they protective or pathogenic? Proteomics. 2015;15(2-3):260–71.
43. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412–20.
44. Sun D, Zhuang X, Zhang S, Deng Z-B, Grizzle W, Miller D, et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev. 2013;65(3):342–7.
45. Van Doormaal FF, Kleinjan A, Di Nisio M, Büller HR, Nieuwland R. Cell-derived microvesicles and cancer. Neth J Med. 2009;67(7):266–73.
46. D’Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012;26(12):1287–99.
47. Henry CM, Hollville E, Martin SJ. Measuring apoptosis by microscopy and flow cytometry. Methods. 2013;61(2):90–7.
48. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013];113(1):1–11.
49. Osteikoetxea X, Balogh A, Szabó-Taylor K, Németh A, Szabó TG, Pálóczi K, et al. Improved Characterization of EV Preparations Based on Protein to Lipid Ratio and Lipid Properties. PLoS One. 2015;10(3):e0121184.
50. Fan G-C. Hypoxic exosomes promote angiogenesis. Blood. 2014;124(25):3669–70.
51. Wang G-J, Liu Y, Qin A, Shah S V, Deng Z, Xiang X, et al. Thymus exosomes-like particles induce regulatory T cells. J Immunol. 2008;181(8):5242–8.
52. Baragaño Raneros A, Suarez-Álvarez B, López- Larrea C. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. Oncoimmunology. 2014;3:e28497.
53. Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G, Alessandro R. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014 348(1-2):71–6.
54. Baixauli F, López-Otín C, Mittelbrunn M. Exosomes and autophagy: coordinated mechanisms for the maintenance of cellular fitness. Front Immunol. 2014;5:403.
55. Ailawadi S, Wang X, Gu H, Fan G-C. Pathologic function and therapeutic potential of exosomes in cardiovascular disease. Biochim Biophys Acta. 2014;1852(1):1–11.
56. Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124(4):555–66.
57. Crunkhorn S. Cancer: Cancer exosomes promote tumorigenesis. Nat Rev Drug Discov. 2014;14(1):16.
58. Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: a busy sorting station for proteins at the crossroads. Histol Histopathol. 2010;25(1):99–112.
59. Andreu Z, Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and function. Front Immunol. 2014;5:442.
60. Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway. Dev Cell. 2011;21(1):77–91.
61. Babst M. MVB vesicle formation: ESCRTdependent, ESCRT-independent and everything in between. Curr Opin Cell Biol. 2011;23(4):452–7.
62. Teo H, Perisic O, González B, Williams RL. ESCRT-II, an endosome-associated complex required for protein sorting: crystal structure and interactions with ESCRT-III and membranes. Dev Cell. 2004;7(4):559–69.
63. Hurley JH, Hanson PI. Membrane budding and scission by the ESCRT machinery: it’s all in the neck. Nat Rev Mol Cell Biol. 2010;11(8):556–66.
64. Sadallah S, Eken C, Schifferli JA. Ectosomes as modulators of inflammation and immunity. Clin Exp Immunol. 2011;163(1):26–32.
65. Hugel B, Martínez MC, Kunzelmann C, Freyssinet J-M. Membrane microparticles: two sides of the coin. Physiology (Bethesda).;20:22–7.
66. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83.
67. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60.
68. Van Dommelen SM, Vader P, Lakhal S, Kooijmans Saa, van Solinge WW, Wood MJ a, et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release. 2012;161(2):635–44.
69. Lai RC, Yeo RWY, Tan KH, Lim SK. Exosomes for drug delivery - a novel application for the mesenchymal stem cell. Biotechnol Adv. 2013;31(5):543–51.
70. El Andaloussi S, Lakhal S, Mäger I, Wood MJ a. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev. 2013 65(3):391–7.
71. Kosaka N, Takeshita F, Yoshioka Y, Hagiwara K, Katsuda T, Ono M, et al. Exosomal tumorsuppressive microRNAs as novel cancer therapy: “exocure” is another choice for cancer treatment. Adv Drug Deliv Rev. 2013;65(3):376–82.
72. Koppers-Lalic D, Hogenboom MM, Middeldorp JM, Pegtel DM. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv Drug Deliv Rev. 2013;65(3):348–56.
73. Van den Boorn JG, Dassler J, Coch C, Schlee M, Hartmann G. Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev. 2013 Mar;65(3):331–5.
74. Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of exosomes as drug delivery vehicles - Endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta. 2014;1846(1):75–87.
75. Van der Meel R, Fens MH a M, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM. Extracellular vesicles as drug delivery systems: Lessons from the liposome field. J Control Release. 2014;195:72–85.
76. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–5.
77. Balazs Da, Godbey W. Liposomes for use in gene delivery. J Drug Deliv. 2011;2011:326497.
78. Shim G, Kim M-G, Park JY, Oh Y-K. Application of cationic liposomes for delivery of nucleic acids. Asian J Pharm Sci. 2013;8(2):72–80.
79. McCaskill J, Singhania R, Burgess M, Allavena R, Wu S, Blumenthal A, et al. Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA. Mol Ther Nucleic Acids. 2013;2:e96.
80. Kikuchi H, Suzuki N, Ebihara K, Morita H, Ishii Y, Kikuchi A, et al. Gene delivery using liposome technology. J Control Release. 1999;62(1-2):269–77.
81. Smyth Templeton N. Liposomal delivery of nucleic acids in vivo. DNA Cell Biol. 2002;21(12):857–67.
82. Ewert KK, Ahmad A, Bouxsein NF, Evans HM, Safinya CR. Non-viral gene delivery with cationic liposome-DNA complexes. Methods Mol Biol. 2008;433:159–75.
83. Vader P, Kooijmans Saa, Stremersch S, Raemdonck K. New considerations in the preparation of nucleic acid-loaded extracellular vesicles. Ther Deliv. 2014;5(2):105–7.
84. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18(9):1606–14.
85. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011;19(10):1769–79.
86. Jang SC, Kim OY, Yoon CM, Choi D, Roh T, Park J, et al. Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors. ACS Nano. 2013;7(9):7698–710.
87. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383–90.
88. Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution and Delivery Efficiency of Unmodified Tumor- Derived Exosomes. J Control Release. 2015;199:145–55.
89. Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, et al. Exosome Delivered Anticancer Drugs Across the Blood- Brain Barrier for Brain Cancer Therapy in Danio Rerio. Pharm Res. 2015;32(6):2003-14.
90. Hood JL, Scott MJ, Wickline SA. Maximizing exosome colloidal stability following electroporation. Anal Biochem. 2014;448:41–9.
91. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release 2015;207:18–30.
92. Fuhrmann G, Serio A, Mazo M, Nair R, Stevens MM. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2014;205:35–44.
93. Safaei R, Larson BJ, Cheng TC, Gibson Ma, Otani S, Naerdemann W, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005;4(10):1595–604.
94. Ouar Z, Bens M, Vignes C, Paulais M, Pringel C, Fleury J, et al. Inhibitors of vacuolar H+- ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J. 2003;370:185–93.
95. Hurwitz S, Terashima M, Mizunuma N, Christopher S. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood. 1997;89(10):3745–55.
96. Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem. 2013;288(44):31761–71.
97. Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014;192:262–70.
98. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8):1183–9.
99. Zhu L, Mahato RI. Lipid and polymeric carriermediated nucleic acid delivery. Expert Opin Drug Deliv. 2010;7(10):1209–26.
100. Dizaj SM, Jafari S, Khosroushahi AY. A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res Lett. 2014;9(1):252.
101. Lotvall J, Valadi H. Cell to Cell Signalling via Exosomes Through esRNA. Cell Adh Migr. 2007;1(3):156–8.
102. Zhao L, Liu W, Xiao J, Cao B. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance. Cancer Lett. 2014;356(2):339–46.
103. Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Lett. 2014;347(1):29–37.
104. Guduric-Fuchs J, O’Connor A, Camp B, O’Neill CL, Medina RJ, Simpson D a. Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics. 2012;13(1):357.
105. Lässer C, Eldh M, Lötvall J. Isolation and characterization of RNA-containing exosomes. J Vis Exp. 2012;(59):e3037.
106. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol. 2009;11(9):1143–9.
107. Hagiwara K, Ochiya T, Kosaka N. A paradigm shift for extracellular vesicles as small RNA carriers: from cellular waste elimination to therapeutic applications. Drug Deliv Transl Res. 2014;4(1):31–7.
108. Momen-Heravi F, Bala S, Bukong T, Szabo G. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine. 2014;10(7):1517–27.
109. Banizs AB, Huang T, Dryden K, Berr SS, Stone JR, Nakamoto RK, et al. In vitro evaluation of endothelial exosomes as carriers for small interfering ribonucleic acid delivery. Int J Nanomedicine. 2014;9:4223–30.
110. Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil Y V, Filatov M V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal. 2013;11:88.
111. Squadrito ML, Baer C, Burdet F, Maderna C, Gilfillan GD, Lyle R, et al. Endogenous RNAs Modulate MicroRNA Sorting to Exosomes and Transfer to Acceptor Cells. Cell Rep. 2014;1432–46.
112. Maguire CA, Balaj L, Sivaraman S, Crommentuijn MHW, Ericsson M, Mincheva- Nilsson L, et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther. 2012;20(5):960–71.
113. Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 2012;30(7):1556–64.
114. Bolukbasi MF, Mizrak A, Ozdener GB, Madlener S, Ströbel T, Erkan EP, et al. miR- 1289 and “Zipcode”-like Sequence Enrich mRNAs in Microvesicles. Mol Ther — Nucleic Acids. 2012;1:e10.
115. Akao Y, Iio A, Itoh T, Noguchi S, Itoh Y, Ohtsuki Y, et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther. 2011;19(2):395–9.
116. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids. 2013;2:e126.
117. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. Mol Ther. 2013;21(1):185–91.
118. Zhang Y, Li L, Yu J, Zhu D, Zhang Y, Li X, et al. Microvesicle-mediated delivery of transforming growth factor β1 siRNA for the suppression of tumor growth in mice. Biomaterials. 2014;35(14):4390–400.
119. Gujrati V, Kim S, Kim S-H, Min JJ, Choy HE, Kim SC, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drugdelivery vehicles for cancer therapy. ACS Nano. 2014;8(2):1525–37.
120. Daya S, Berns KI. Gene therapy using adenoassociated virus vectors. Clin Microbiol Rev. 2008;21(4):583–93.
121. Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z. MiRNA in plasma exosome is stable under different storage conditions. Molecules. 2014;19:1568–75.
122. Cheng L, Sharples Ra, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 2014;3:1–14.
123. Grange C, Tapparo M, Bruno S, Chatterjee D, Quesenberry PJ, Tetta C, et al. Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging. Int J Mol Med. 2014;33(5):1055–63.
124. Wiklander OPB, Nordin JZ, O’Loughlin A, Gustafsson Y, Corso G, Mäger I, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015;4:26316.
125. Morishita M, Takahashi Y, Nishikawa M, Sano K, Kato K, Yamashita T, et al. Quantitative Analysis of Tissue Distribution of the B16BL6- Derived Exosomes Using a Streptavidin- Lactadherin Fusion Protein and Iodine-125- Labeled Biotin Derivative After Intravenous Injection in Mice. J Pharm Sci. 2015;104(2):705–13.
126. Takahashi Y, Nishikawa M, Shinotsuka H, Matsui Y, Ohara S, Imai T, et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol. 2013;165(2):77–84.
127. Lai CP, Mardini O, Ericsson M, Prabhakar S, Maguire CA, Chen JW, et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano. 2014;8(1):483–94.
128. Smyth T, Petrova K, Payton NM, Persaud I, Redzic JS, Graner MW, et al. Surface functionalization of exosomes using click chemistry. Bioconjug Chem. 2014;25(10):1777–84.
129. Beauvillain C, Ruiz S, Guiton R, Bout D, Dimier-Poisson I. A vaccine based on exosomes secreted by a dendritic cell line confers protection against T. gondii infection in syngeneic and allogeneic mice. Microbes Infect. 2007;9(14-15):1614–22.
130. Hung ME, Leonard JN. Stabilization of Exosome-targeting Peptides via Engineered Glycosylation. J Biol Chem. 2015;290(13):8166–72.